These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9144103)

  • 21. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics.
    Potkin SG; Fleming K; Jin Y; Gulasekaram B
    J Clin Psychopharmacol; 2001 Oct; 21(5):479-83. PubMed ID: 11593072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia.
    Lee MA; Jayathilake K; Meltzer HY
    Schizophr Res; 1999 May; 37(1):1-11. PubMed ID: 10227103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of clozapine on cognitive function and regional cerebral blood flow in the negative symptom profile schizophrenia.
    Zhao J; He X; Liu Z; Yang D
    Int J Psychiatry Med; 2006; 36(2):171-81. PubMed ID: 17154147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive functioning in schizophrenia with or without diabetes.
    Guo X; Zhang Z; Zhu W; Lian N; Lu H; Zhao J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Aug; 36(8):724-7. PubMed ID: 21937796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antipsychotic medication and cognitive function in schizophrenia.
    Hori H; Noguchi H; Hashimoto R; Nakabayashi T; Omori M; Takahashi S; Tsukue R; Anami K; Hirabayashi N; Harada S; Saitoh O; Iwase M; Kajimoto O; Takeda M; Okabe S; Kunugi H
    Schizophr Res; 2006 Sep; 86(1-3):138-46. PubMed ID: 16793238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does cognitive impairment in treatment-resistant and ultra-treatment-resistant schizophrenia differ from that in treatment responders?
    Anderson VM; McIlwain ME; Kydd RR; Russell BR
    Psychiatry Res; 2015 Dec; 230(3):811-8. PubMed ID: 26564550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal Wisconsin card sorting performance in schizophrenia patients in rehabilitation.
    Bryson G; Greig T; Lysaker P; Bell M
    Appl Neuropsychol; 2002; 9(4):203-9. PubMed ID: 12584074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():35-40. PubMed ID: 9766618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia.
    Gold S; Arndt S; Nopoulos P; O'Leary DS; Andreasen NC
    Am J Psychiatry; 1999 Sep; 156(9):1342-8. PubMed ID: 10484943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A new therapeutic approach tp drug-resistant schizophrenia: clozapine. Long-term prospective study in 16 patients].
    Jalenques I; Coudert AJ
    Acta Psychiatr Belg; 1992; 92(6):323-38. PubMed ID: 1364281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of ziprasidone and clozapine in treatment-resistant schizophrenia.
    Zink M; Mase E; Dressing H
    Hum Psychopharmacol; 2004 Jun; 19(4):271-3. PubMed ID: 15181656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies.
    Goldberg TE; Weinberger DR
    J Clin Psychiatry; 1996; 57 Suppl 9():62-5. PubMed ID: 8823353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuropsychological effects of maintenance treatment with Clozapine in Treatment-Resistant Psychotic Disorder.
    Carceller-Sindreu M; Portella MJ; Carmona C; Rametti G; Puigdemont D; Figueras M; Fernández-Vidal A; Villalta L; Alvarez E
    Actas Esp Psiquiatr; 2014; 42(2):68-73. PubMed ID: 24715364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive dysfunction in schizophrenia.
    Lublin H
    Acta Psychiatr Scand Suppl; 2001; (408):5-9. PubMed ID: 11730073
    [No Abstract]   [Full Text] [Related]  

  • 37. [Clozapine: neuropsychological and neuroimaging studies].
    Pérez-Gómez M; Junqué C
    Actas Esp Psiquiatr; 1999; 27(5):341-6. PubMed ID: 10545667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment.
    Meltzer HY; Thompson PA; Lee MA; Ranjan R
    Neuropsychopharmacology; 1996 Mar; 14(3 Suppl):27S-33S. PubMed ID: 8866741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.
    Hoff AL; Faustman WO; Wieneke M; Espinoza S; Costa M; Wolkowitz O; Csernansky JG
    Neuropsychopharmacology; 1996 Oct; 15(4):361-9. PubMed ID: 8887990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning.
    Grace J; Bellus SB; Raulin ML; Herz MI; Priest BL; Brenner V; Donnelly K; Smith P; Gunn S
    Psychiatr Serv; 1996 Jan; 47(1):41-5. PubMed ID: 8925344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.